Brokerages Set Atyr PHARMA INC (NASDAQ:ATYR) PT at $18.60

Shares of Atyr PHARMA INC (NASDAQ:ATYR) have earned a consensus recommendation of “Buy” from the seven brokerages that are presently covering the firm, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $18.60.

Several brokerages have issued reports on ATYR. Cantor Fitzgerald initiated coverage on shares of Atyr PHARMA in a report on Monday, January 6th. They set an “overweight” rating on the stock. HC Wainwright reiterated a “buy” rating and set a $35.00 price objective on shares of Atyr PHARMA in a research note on Friday, March 14th. Leerink Partnrs raised shares of Atyr PHARMA to a “strong-buy” rating in a research note on Tuesday, February 18th. Finally, Leerink Partners initiated coverage on Atyr PHARMA in a research report on Tuesday, February 18th. They set an “outperform” rating and a $16.00 price objective on the stock.

Institutional Trading of Atyr PHARMA

Institutional investors have recently bought and sold shares of the stock. Federated Hermes Inc. acquired a new stake in shares of Atyr PHARMA during the fourth quarter worth $53,093,000. Point72 Asset Management L.P. purchased a new position in Atyr PHARMA in the 4th quarter worth $17,677,000. Tikvah Management LLC acquired a new stake in Atyr PHARMA during the 4th quarter worth about $8,908,000. Woodline Partners LP purchased a new stake in Atyr PHARMA during the 4th quarter valued at about $6,092,000. Finally, Alyeska Investment Group L.P. acquired a new position in shares of Atyr PHARMA in the fourth quarter valued at about $4,628,000. 61.72% of the stock is currently owned by institutional investors and hedge funds.

Atyr PHARMA Stock Down 0.7 %

Shares of NASDAQ:ATYR opened at $2.99 on Wednesday. The business’s 50 day moving average is $3.42 and its 200 day moving average is $3.28. The stock has a market cap of $265.69 million, a P/E ratio of -3.18 and a beta of 0.95. Atyr PHARMA has a 52-week low of $1.42 and a 52-week high of $4.66. The company has a quick ratio of 5.41, a current ratio of 5.41 and a debt-to-equity ratio of 0.02.

Atyr PHARMA (NASDAQ:ATYR) last issued its earnings results on Thursday, March 13th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.05. Sell-side analysts predict that Atyr PHARMA will post -0.91 EPS for the current year.

About Atyr PHARMA

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.